Compounds > troleandomycin
Page last updated: 2024-09-05

troleandomycin and verapamil

troleandomycin has been researched along with verapamil in 13 studies

Compound Research Comparison

Studies
(troleandomycin)		Trials
(troleandomycin)		Recent Studies (post-2010)
(troleandomycin)		Studies
(verapamil)		Trials
(verapamil)		Recent Studies (post-2010) (verapamil)
569262317,6211,5272,067

Protein Interaction Comparison

ProteinTaxonomytroleandomycin (IC50)verapamil (IC50)
Solute carrier family 22 member 1 Homo sapiens (human)6.8
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)0.2
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.297
ATP-dependent translocase ABCB1Mus musculus (house mouse)2
ATP-dependent translocase ABCB1Homo sapiens (human)2.2346
Cytochrome P450 3A4Homo sapiens (human)3.8008
Alpha-2A adrenergic receptorHomo sapiens (human)0.579
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)3.02
ATP-dependent translocase ABCB1Mus musculus (house mouse)10
Catechol O-methyltransferaseHomo sapiens (human)0.2
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)8
Histamine H2 receptorHomo sapiens (human)2.59
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.442
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.297
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)3.02
Sodium-dependent serotonin transporterHomo sapiens (human)0.24
Multidrug resistance-associated protein 1 Homo sapiens (human)5.598
D(3) dopamine receptorHomo sapiens (human)0.186
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.165
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)6.8
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)0.2
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.3945
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)0.2
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)0.175
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.1934

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (15.38)18.2507
2000's6 (46.15)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ1
Dansette, PM; Fontana, E; Poli, SM1
Pratim Roy, P; Roy, K1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1
Bader, A; Christians, U; Gonschior, AK; Hackbarth, I; Lampen, A; Sewing, KF; von Engelhardt, W1
Aguilar, AJ; Grace, JM; Skanchy, DJ1
Kohno, Y; Suzuki, A; Yamamoto, T1
Hall, K; Meredith, S; Murray, KT; Narasimhulu, SS; Ray, WA; Stein, CM1
Al-Shurbaji, A; Annas, A; Artursson, P; Lazorova, L; Svensson, JO; Yasar, U1
Chen, Y; Fretland, AJ; Liu, L; Monshouwer, M1
Albaugh, DR; Fisher, MB; Fullenwider, CL; Hutzler, JM1
Reinen, J; Smit, M; Wenker, M1

Reviews

1 review(s) available for troleandomycin and verapamil

ArticleYear
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Current drug metabolism, 2005, Volume: 6, Issue:5

    Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic

2005

Other Studies

12 other study(ies) available for troleandomycin and verapamil

ArticleYear
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
    Biochemical and biophysical research communications, 2001, Nov-30, Volume: 289, Issue:2

    Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors

2001
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:7

    Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013
Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber.
    British journal of pharmacology, 1996, Volume: 117, Issue:8

    Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Gastric Mucosa; Immunosuppressive Agents; Ketoconazole; Oxidoreductases, N-Demethylating; Swine; Tacrolimus; Troleandomycin; Vasodilator Agents; Verapamil

1996
Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A.
    Xenobiotica; the fate of foreign compounds in biological systems, 1999, Volume: 29, Issue:7

    Topics: Adult; Aged; Antifungal Agents; Antimalarials; Artemisinins; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Glycyrrhiza; Humans; Inactivation, Metabolic; Inhibitory Concentration 50; Isoenzymes; Ketoconazole; Liver; Male; Miconazole; Microsomes, Liver; Middle Aged; Oxidoreductases, N-Demethylating; Paeonia; Quinidine; Recombinant Proteins; Sesquiterpenes; Sulfaphenazole; Troleandomycin; Vasodilator Agents; Verapamil

1999
High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method.
    Xenobiotica; the fate of foreign compounds in biological systems, 2004, Volume: 34, Issue:1

    Topics: Amiodarone; Animals; Baculoviridae; Binding, Competitive; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Enzyme Inhibitors; Fluorescence; Humans; Inhibitory Concentration 50; Ketoconazole; Miconazole; Midazolam; Propafenone; Quinolines; Recombinant Proteins; Troleandomycin; Verapamil

2004
Oral erythromycin and the risk of sudden death from cardiac causes.
    The New England journal of medicine, 2004, Sep-09, Volume: 351, Issue:11

    Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Confounding Factors, Epidemiologic; Cytochrome P-450 CYP3A; Death, Sudden, Cardiac; Diltiazem; Drug Interactions; Erythromycin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Nitroimidazoles; Oxidoreductases, N-Demethylating; Risk; Troleandomycin; Verapamil

2004
Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein.
    Xenobiotica; the fate of foreign compounds in biological systems, 2005, Volume: 35, Issue:8

    Topics: ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Caco-2 Cells; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Isonipecotic Acids; Ketoconazole; Kinetics; Meperidine; Microsomes, Liver; Mutagenesis, Site-Directed; Phenols; Substrate Specificity; Sulfaphenazole; Troleandomycin; Verapamil

2005
Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:11

    Topics: Cryopreservation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Erythromycin; Hepatocytes; Humans; Microsomes, Liver; Pharmacokinetics; Risk Assessment; Time Factors; Troleandomycin; Verapamil

2011
Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:7

    Topics: Cells, Cultured; Clarithromycin; Cryopreservation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Hepatocytes; Humans; Kinetics; Microsomes, Liver; Troleandomycin; Verapamil

2012
Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.
    European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:6

    Topics: Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Dihydralazine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Microsomes, Liver; Mifepristone; Paroxetine; Theophylline; Troleandomycin; Verapamil

2018